Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF 04929113

Known as: SNX-5422 Mesylate, PF04929113, SNX-5422 
The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Although prostate cancer responds initially to androgen ablation therapies, progression to castration-resistant… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Spermiogenesis is characterized by a profound morphological differentiation of the haploid spermatid into spermatozoa. The testis… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
BACKGROUND Heat shock protein (HSP)90 regulates the function of proteins responsible for cell growth and survival, is… Expand
Is this relevant?
2012
2012
Hsp90 is an abundant protein in mammalian cells. It forms several discrete complexes, each containing distinct groups of co… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2010
2010
A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Heat-shock protein 90 (Hsp90) acts as a molecular chaperone required for maintaining the conformational stability of client… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2009
2009
PURPOSE We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
14613 Background: SNX-5422 is an oral pro-drug of SNX-2112, a potent and highly selective small-molecule inhibitor of the… Expand
Is this relevant?